Hear Vicore Pharma’s CEO, Ahmed Mousa speak to Optimum's Richard Staines on their new treatment for Idiopathic Pulmonary Fibrosis (IPF), C21. It aims to improve available treatments for patients of IPF by halting the progression of fibrosis and has the aim of restoring lung function.
Hosted on Acast. See acast.com/privacy for more information.
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More